1. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, 2000: 3257-3301.

2. Singh I, Moser AE, Moser HW, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res 1984; 18(3):286-290.

3. Singh I, Moser AE, Goldfischer S, Moser HW. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A 1984; 81(13):4203-4207.

4. Mosser J, Douar AM, Sarde CO et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361(6414):726-730.

5. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8:67-113.

6. Cartier N, Lopez J, Moullier P et al. Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci U S A 1995; 92(5):1674-1678.

7. Steinberg SJ, Kemp S, Braiterman LT, Watkins PA. Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy. Ann Neurol 1999; 46(3):409-412.

8. Kemp S, Pujol A, Waterham HR et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 2001; 18(6):499-515.

9. Bezman L, Moser AB, Raymond GV et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49(4):512-517.

10. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997; 120 ( Pt 8):1485-508.

11. Aubourg P. X-linked adrenoleukodystrophy. In: Moser HW, editor. Handbook of Clinical Neurology: Neurodystrophies and Neurolipidoses. Amsterdam: Elsevier Science BV, 1996: 447-483.

12. van Geel BM, Assies J, Wanders RJ, Barth PG. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry 1997; 63(1):4-14.

13. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51(6):630-643.

14. Ito M, Blumberg BM, Mock DJ et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001; 60(10):1004-1019.

15. Kumar AJ, Rosenbaum AE, Naidu S et al. Adrenoleukodystrophy: correlating MR imaging with CT. Radiology 1987; 165(2):497-504.

16. Kruse B, Barker PB, van Zijl PC, Duyn JH, Moonen CT, Moser HW. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994; 36(4):595-608.

17. Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998; 29(5):254-264.

18. Eichler FS, Barker PB, Cox C et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X- linked adrenoleukodystrophy. Neurology 2002; 58(6):901-907.

19. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59(2):89-102.

20. Powers JM, DeCiero DP, Cox C et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60(5):493-501.

21. van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001; 49(2):186-194.

22. Brennemann W, Kohler W, Zierz S, Klingmuller D. Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy. Neurology 1996; 47(2):605.

23. Powers JM, Moser HW, Moser AB, Ma CK, Elias SB, Norum RA. Pathologic findings in adrenoleukodystrophy heterozygotes. Arch Pathol Lab Med 1987; 111(2):151-153.

24. el-Deiry SS, Naidu S, Blevins LS, Ladenson PW. Assessment of adrenal function in women heterozygous for adrenoleukodystrophy. J Clin Endocrinol Metab 1997; 82(3):856-860.

25. Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996; 81(2):470-474.

26. Jorge P, Quelhas D, Oliveira P, Pinto R, Nogueira A. X-linked adrenoleukodystrophy in patients with idiopathic Addison disease. Eur J Pediatr 1994; 153(8):594-597.

27. Moser AB, Kreiter N, Bezman L et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45(1):100-110.

28. Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab 1999; 66(2):128-136.

29. Moser AB, Moser HW. The prenatal diagnosis of X-linked adrenoleukodystrophy. Prenat Diagn 1999; 19(1):46-48.

30. Kelley RI, Datta NS, Dobyns WB et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 1986; 23(4):869-901.

31. Tullio-Pelet A, Salomon R, Hadj-Rabia S et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000; 26(3):332-335.

32. Gazarian M, Cowell CT, Bonney M, Grigor WG. The "4A" syndrome: adrenocortical insufficiency associated with achalasia, alacrima, autonomic and other neurological abnormalities. Eur J Pediatr 1995; 154(1):18-23.

33. Wise JE, Matalon R, Morgan AM, McCabe ER. Phenotypic features of patients with congenital adrenal hypoplasia and glycerol kinase deficiency. Am J Dis Child 1987; 141(7):744-747.

34. Powers JM, Schaumburg HH. The adrenal cortex in adreno-leukodystrophy. Arch Pathol 1973; 96(5):305-310.

35. Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked Schilder's disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol 1974; 76(3):481-491.

36. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976; 26(4):851-860.

37. Powers JM, Moser HW, Moser AB, Schaumburg HH. Fetal adrenoleukodystrophy: the significance of pathologic lesions in adrenal gland and testis. Hum Pathol 1982; 13(11):1013-1019.

38. Peckham RS, Marshall MC Jr, Rosman PM, Farag A, Kabadi U, Wallace EZ. A variant of adrenomyeloneuropathy with hypothalamic-pituitary dysfunction and neurologic remission after glucocorticoid replacement therapy. Am J Med 1982; 72(1):173-176.

39. Aubourg P, Blanche S, Jambaque I et al. Reversal of early neurologic and neuroradiologic manifestations of X- linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 1990; 322(26):1860-1866.

40. Shapiro E, Krivit W, Lockman L et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356(9231):713-718.

41. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988; 239(4837):290-292.

42. Moser HW, Loes DJ, Melhem ER et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000; 31(5):227-239.

43. Rizzo WB, Leshner RT, Odone A et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39(11):1415-1422.

44. van Geel BM, Assies J, Haverkort EB et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J Neurol Neurosurg Psychiatry 1999; 67(3):290-299.

45. Assies J, van Geel B, Weverling GJ, Haverkort EB, Barth PG. Endocrine evaluation during dietary therapy for adrenomyeloneuropathy. Bhatt HR, James GHT, Besser GM, Bottazzo GF, Keen HE, editors. Advances in Thomas Addison's Diseases. 1, 191-198. 1994. Bristol, Journal of Endocrinology.

46. Kemp S, Wei HM, Lu JF et al. Gene redundancy and pharmacological gene therapy: implications for X- linked adrenoleukodystrophy. Nat Med 1998; 4(11):1261-1268.

47. Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 1998; 339(10):702-703.

48. Pai GS, Khan M, Barbosa E et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 2000; 69(4):312-322.

49. Doerflinger N, Miclea JM, Lopez J et al. Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells. Hum Gene Ther 1998; 9(7):1025-1036.